Fennec Pharmaceuticals (FENC) Competitors $5.08 -0.02 (-0.39%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$5.08 0.00 (-0.10%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FENC vs. REPL, VECT, VALN, OPT, IMTX, DNA, CGEM, RLAY, MGTX, and SANAShould you be buying Fennec Pharmaceuticals stock or one of its competitors? The main competitors of Fennec Pharmaceuticals include Replimune Group (REPL), VectivBio (VECT), Valneva (VALN), Opthea (OPT), Immatics (IMTX), Ginkgo Bioworks (DNA), Cullinan Therapeutics (CGEM), Relay Therapeutics (RLAY), MeiraGTx (MGTX), and Sana Biotechnology (SANA). These companies are all part of the "biological products, except diagnostic" industry. Fennec Pharmaceuticals vs. Replimune Group VectivBio Valneva Opthea Immatics Ginkgo Bioworks Cullinan Therapeutics Relay Therapeutics MeiraGTx Sana Biotechnology Replimune Group (NASDAQ:REPL) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and community ranking. Do institutionals & insiders have more ownership in REPL or FENC? 92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 55.5% of Fennec Pharmaceuticals shares are owned by institutional investors. 8.8% of Replimune Group shares are owned by insiders. Comparatively, 11.0% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is REPL or FENC more profitable? Replimune Group has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -2.30%. Fennec Pharmaceuticals' return on equity of -53.38% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -54.84% -42.97% Fennec Pharmaceuticals -2.30%-53.38%-2.08% Which has more risk & volatility, REPL or FENC? Replimune Group has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Does the MarketBeat Community believe in REPL or FENC? Fennec Pharmaceuticals received 33 more outperform votes than Replimune Group when rated by MarketBeat users. Likewise, 66.67% of users gave Fennec Pharmaceuticals an outperform vote while only 64.02% of users gave Replimune Group an outperform vote. CompanyUnderperformOutperformReplimune GroupOutperform Votes16964.02% Underperform Votes9535.98% Fennec PharmaceuticalsOutperform Votes20266.67% Underperform Votes10133.33% Do analysts recommend REPL or FENC? Replimune Group currently has a consensus target price of $19.43, suggesting a potential upside of 143.16%. Fennec Pharmaceuticals has a consensus target price of $13.67, suggesting a potential upside of 169.03%. Given Fennec Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Fennec Pharmaceuticals is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has higher valuation and earnings, REPL or FENC? Fennec Pharmaceuticals has higher revenue and earnings than Replimune Group. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$215.79M-$3.07-2.60Fennec Pharmaceuticals$47.54M2.95-$16.05M-$0.06-84.67 Does the media prefer REPL or FENC? In the previous week, Replimune Group had 4 more articles in the media than Fennec Pharmaceuticals. MarketBeat recorded 4 mentions for Replimune Group and 0 mentions for Fennec Pharmaceuticals. Replimune Group's average media sentiment score of 1.11 beat Fennec Pharmaceuticals' score of 0.00 indicating that Replimune Group is being referred to more favorably in the media. Company Overall Sentiment Replimune Group Positive Fennec Pharmaceuticals Neutral SummaryFennec Pharmaceuticals beats Replimune Group on 10 of the 17 factors compared between the two stocks. Get Fennec Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FENC vs. The Competition Export to ExcelMetricFennec PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$140.18M$2.84B$5.30B$7.35BDividend YieldN/A1.86%5.45%4.30%P/E Ratio-50.7930.4821.8617.81Price / Sales2.95441.91380.6697.70Price / CashN/A168.6838.2634.64Price / Book-11.813.466.453.98Net Income-$16.05M-$72.06M$3.22B$247.81M1 Month Performance-23.84%-16.76%-9.76%-7.94%1 Year Performance-45.61%-26.05%11.49%1.52% Fennec Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FENCFennec Pharmaceuticals1.4506 of 5 stars$5.08-0.4%$13.67+169.0%-46.9%$140.18M$47.54M-50.79N/AGap DownREPLReplimune Group3.4864 of 5 stars$7.51+2.2%$19.43+158.7%+14.6%$578.38MN/A-2.45210News CoveragePositive NewsVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeVALNValneva1.7711 of 5 stars$7.05+12.1%$16.00+127.0%-16.5%$572.89M$169.58M-54.23700Analyst ForecastOPTOpthea0.7365 of 5 stars$3.41+7.2%$1.33-60.9%+0.3%$524.84M$87,666.000.008Gap UpIMTXImmatics2.4946 of 5 stars$4.23+2.2%$16.67+294.0%-58.5%$514.16M$155.84M-6.41260Short Interest ↓Gap DownDNAGinkgo Bioworks0.6496 of 5 stars$8.37+3.1%$4.58-45.3%N/A$485.75M$227.04M-0.64640News CoverageGap DownCGEMCullinan Therapeutics2.2346 of 5 stars$7.74+0.4%$32.86+324.5%-56.3%$452.89MN/A-2.7330Analyst ForecastNews CoveragePositive NewsRLAYRelay Therapeutics2.7065 of 5 stars$2.57+6.2%$19.80+670.4%-56.0%$435.67M$10.01M-0.98330Analyst ForecastNews CoverageGap DownMGTXMeiraGTx4.3534 of 5 stars$5.48+5.4%$24.50+347.1%+8.0%$432.13M$33.28M-4.53300High Trading VolumeSANASana Biotechnology2.304 of 5 stars$1.81+2.8%$10.80+496.7%-78.7%$407.30MN/A-1.29380 Related Companies and Tools Related Companies Replimune Group Alternatives VectivBio Alternatives Valneva Alternatives Opthea Alternatives Immatics Alternatives Ginkgo Bioworks Alternatives Cullinan Therapeutics Alternatives Relay Therapeutics Alternatives MeiraGTx Alternatives Sana Biotechnology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FENC) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FENC Stock Free FENC Stock Alerts